KCTD17

Across TCGA pan-cancer cohorts, KCTD17 RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated KCTD17 data layer compared with 1 for mutation status and 3 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher KCTD17 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated KCTD17 expression acts as an unfavorable survival marker, although some lineages such as SCLC and READ show a favorable association.

KIRC, UVM, and MESO are the cancer types where KCTD17 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.567	0.688	<.001	146	view →
UVM	OS	Median	All	0.377	0.857	<.001	134	view →
MESO	OS	Median	All	0.280	0.508	<.001	93	view →
ACC	DFS	Median	II,III,IV	0.485	0.913	<.001	66	view →
SCLC	OS	Quartile	All	0.815	0.431	<.001	63	view →
LIHC	OS	Quartile	All	0.475	0.713	<.001	44	view →
LAML	DFS	Quartile	All	0.364	0.731	<.001	36	view →
READ	DFS	Median	III,IV	0.741	0.305	.005	36	view →
HNSC	OS	Quartile	All	0.470	0.781	<.001	33	view →
LUSC	DFS	Quartile	III,IV	0.097	1.000	.001	28	view →
UCEC	OS	Tertile	All	0.824	0.901	.013	14	view →
LGG	OS	Tertile	All	0.725	0.841	.004	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

KCTD17–KIRC (OS)

Open the KIRC breakdown →